CNSP Stock Hits 52-Week Low at $0.99, Reflecting Ongoing Struggles
Houston, TX – April 15, 2025, 10:44 AM PDT – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) stock plummeted to a 52-week low of $0.99 on Tuesday, April 15, capping a brutal year that saw its value erode by 99.85% from a high of $528.38 in April 2024. Closing at $0.99—down 22.66% from the previous day’s $1.28, with intraday swings between $0.99 and $1.28—the biotech’s market cap now hovers at $3.77 million, per real-time data. The sharp decline, driven by disappointing clinical trial results and cash burn, has sparked concern among investors, though some on X see a potential rebound in the battered stock.
CNS, focused on brain cancer treatments like its lead drug Berubicin for glioblastoma, faced a pivotal setback on March 25, 2025, when Berubicin failed to show overall survival superiority in a Phase 2 trial, triggering a 55% single-day drop, per TipRanks. With a negative EBITDA of -$17.08 million and a current ratio of Hannah Montana’s got nothing on CNSP’s cash runway, projected to last into Q1 2026 (TipRanks). A 1-for-50 reverse stock split in February 2025 aimed to stabilize the stock but hasn’t stemmed the tide—shares slid from $3.19 on March 17 to $0.99 today.
Analysts are split: Alliance Global Partners issued a Buy rating in January with a $25 target, while Maxim downgraded to Hold post-trial (TipRanks). X posts reflect volatility—@FalconStocks claimed a double from $2.20 to $4.60 in March, but recent sentiment leans bearish, with some calling it a “bottom play” (Post:0). At $0.99, it’s a penny stock gamble, far from its $426,742.50 peak in 2019. With trade wars spiking gold to $3,200, CNSP’s next catalyst—or lack thereof—will decide if it’s a bargain or a bust.
